In a bold blend of art and biology, poetry meets an unkillable microbe
Category: biotech/medical – Page 67
‘Skin in a syringe’: Researchers develop wound treatment with injectable cell technology
Researchers have created what could be called “skin in a syringe.” The gel containing live cells can be 3D printed into a skin transplant, as shown in a study conducted on mice. This technology may lead to new ways to treat burns and severe wounds. The study was led by the Center for Disaster Medicine and Traumatology and Linköping University in Sweden.
As long as we have healthy skin, we do not give it much thought. However, if we get major wounds or other injuries, it becomes clear that the skin is the body’s protection from the outside world. Helping the body restore the skin barrier after a serious burn can therefore be a matter of life and death.
Large burns are often treated by transplanting a thin layer of the top part of the skin, the epidermis. This is basically composed of a single cell type. Transplanting only this part of the skin leads to severe scarring.
New Study Demonstrates Improved Survival With Combination of Lurbinectedin and Atezolizumab for Extensive-Stage Small Cell Lung Cancer
“Immunotherapy has improved survival outcomes for patients with extensive-stage small cell lung cancer (ES-SCLC), marking meaningful progress in a historically challenging disease. However, despite these advances, long-term outcomes remain suboptimal, underscoring the need for better strategies. The integration of lurbinectedin—a novel DNA-damaging agent—into the maintenance setting alongside atezolizumab following initial chemo-immunotherapy represents an important next step. This approach offers a way to extend disease control and may signal a shift toward more durable benefit for patients,” said Charu Aggarwal, MD, MPH, FASCO, Leslye M Heisler Professor of Lung Cancer Excellence at University of Pennsylvania – Abramson Cancer Center, and an ASCO Expert in lung cancer.
ALEXANDRIA, Va. — Results from a global phase 3 clinical trial found that maintenance therapy with a combination of lurbinectedin and atezolizumab helped some patients with extensive-stage small cell lung cancer (ES-SCLC) live longer compared to maintenance therapy with atezolizumab alone. The research will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3 in Chicago.
About the Study
“While the introduction of immunotherapy in first-line treatment has improved outcomes, advanced small cell lung cancer remains difficult to treat. The phase 3 IMforte trial shows that the new treatment combination of lurbinectedin and atezolizumab given as maintenance therapy after first-line treatment helps people live longer and reduces the risk of disease progression or death. This outcome represents a major milestone and could provide a much-needed option for advancing the treatment of this aggressive disease,” said lead study author Luis G. Paz Ares, MD, PhD, 12 de Octubre University Hospital in Madrid, Spain.
Equipping living cells with logic gates to fight cancer
One of the most exciting developments in cancer treatment is a wave of new cell therapies that train a patient’s immune system to attack cancer cells. Such therapies have saved the lives of patients with certain aggressive cancers and few other options. Most of these therapies work by teaching immune cells to recognize and attack specific proteins on the surface of cancer cells.
Unfortunately, most proteins found on cancer cells aren’t unique to tumors. They’re also often present on healthy cells, making it difficult to target cancer aggressively without triggering dangerous attacks on other tissue. The problem has limited the application of cell therapies to a small subset of cancers.
Now Senti Bio is working to create smarter cell therapies using synthetic biology. The company, which was founded by former MIT faculty member and current MIT Research Associate Tim Lu ’03, MEng ’03, PhD ’08 and Professor James Collins, is equipping cells with gene circuits that allow the cells to sense and respond to their environments.
Founded by MIT researchers, Senti Bio is is working to create smarter cell therapies for cancer using synthetic biology. The company equips cells with gene circuits that allow the cells to respond to their environments.
Scientific panel puts new guardrails around stem cell-based embryo models
An influential scientific panel is pumping the brakes on stem cell-based embryo models — an umbrella term for the increasingly complex structures researchers are building from stem cells and growing in the lab to mimic aspects of embryonic development. In new guidelines released Monday, the International Society for Stem Cell Research called for stricter oversight of studies involving such models and the establishment of red lines against using them for certain activities.
Specifically, the latest guidelines say that researchers should not use any stem cell-based embryo models to try to start a pregnancy in a person or animal or grow them in an artificial womb to the point of viability, because of broad consensus that such experiments would be unethical. The new restrictions also extend to purposes beyond research, including commercial and reproductive.
Although the models that scientists have built thus far remain too primitive to reach that developmental milestone, the updated guidance is aimed at addressing an explosion of rapid advances in the field over the past several years that are already raising thorny ethical dilemmas.
Invisible polymer film offers powerful conductivity for smart devices
Scientists at La Trobe University have produced a new, powerful electricity-conducting material in research which could revolutionize smartphones and wearable technologies like medical devices.
The new technique uses hyaluronic acid, well known due to its popularity in skincare, applied directly to a gold-plated surface to create a thinner, more durable film, or polymer, used to conduct electricity in devices like biosensors.
Lead researcher Associate Professor Wren Greene said the technique could lead to major improvements in the function, cost and usability of devices like touchscreens and wearable biosensors.
New Research Confirms Weight-Loss Drug Link With Sudden Vision Loss
Drugs such as Ozempic, Wegovy and Mounjaro (known as semaglutide and tirzepatide) have changed the way clinicians manage diabetes and obesity around the world.
Collectively known as GLP-1 agonists, these drugs mimic the hormone GLP-1. This limits both hunger and interest in food, helping users lose weight, and helps control blood sugar levels.
But two new studies published today show that people taking these drugs may have a small increased risk of serious eye conditions and vision loss.
Invisible Polymer Film Could Revolutionize Smart Devices with Metal-Like Conductivity
From smartphones and smartwatches to medical biosensors, the demand for thinner, lighter, and more powerful electronic components continues to grow. Now, scientists at La Trobe University have developed a groundbreaking invisible polymer film that conducts electricity as effectively as metals, yet is flexible, durable, and scalable for mass production. This innovation could transform not only consumer electronics but also advanced health monitoring devices and wearable technology.
The Breakthrough: Tethered Dopant Templating
For decades, conductive polymers — synthetic materials capable of carrying an electrical current — have been hailed as a promising alternative to metals in electronics. However, they have struggled to achieve the necessary combination of thinness, transparency, conductivity, and durability required for high-performance devices.
Neurodegenerative diseases: Research establishes causal link between mitochondrial dysfunction and cognitive symptoms
Mitochondria, the tiny organelles without which our bodies would be deprived of energy, are gradually revealing their mysteries. In a study published in Nature Neuroscience, researchers from Inserm and the University of Bordeaux at the NeuroCentre Magendie, in collaboration with researchers from the Université de Moncton in Canada, have for the first time succeeded in establishing a causal link between mitochondrial dysfunction and the cognitive symptoms associated with neurodegenerative diseases.
Thanks to the creation of a specific and unprecedented tool, they succeeded in increasing mitochondrial activity in animal models of neurodegenerative diseases, where they observed an improvement in memory deficit symptoms. While these are only initial results, they open the door to considering mitochondria as a new therapeutic target.
The mitochondrion is a small intracellular organelle that provides the energy needed by the cell to function properly. The brain is one of the most energy-demanding organs, and neurons rely on the energy produced by mitochondria to communicate with one another. Indeed, when mitochondrial activity is impaired, neurons do not have the energy required to function correctly.